Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

19

Revenue 2017

Keytruda

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Keytruda was produced by Merck & Co..

MSD withdraws Keytruda’s US indication for small cell lung cancer

MSD withdraws Keytruda’s US indication for small cell lung cancer Keytruda failed to meet this requirement in the KEYNOTE-604 trial, as announced in January 2020. ... Keytruda remains a foundational treatment for certain patients with metastatic non-small cell lung cancer.

Sanofi, Regeneron’s Libtayo scores first-line NSCLC approval in the US

Sanofi, Regeneron’s Libtayo scores first-line NSCLC approval in the US In its new NSCLC setting, Libtayo will take on Merck &Co/MSD’s blockbuster checkpoint inhibitor Keytruda (pembrolizumab). ... Keytruda has become the new standard-of-care treatment for newly-diagnosed advanced NSCLC, after first winning approval in

AZ withdraws Imfinzi in the US for advanced bladder cancer after post-marketing study fail

AZ withdraws Imfinzi in the US for advanced bladder cancer after post-marketing study fail NMIBC). A number of immunotherapies are approved for bladder cancer, including Merck &Co/MSD’s Keytruda (pembrolizumab) which became the first checkpoint inhibitor to be approved in the US for NMIBC

New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer

New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer The overall response rate (ORR) for Keytruda plus Lenvima-treated patients was 71% compared to 36.1% in the Sutent group. ... In this trial, Keytruda plus Lenvima demonstrated superior efficacy benefits compared with Sutent.

BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer

BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer Both Opdivo combinations will compete with Merck &Co/MSD’s blockbuster checkpoint inhibitor Keytruda (pembrolizumab) plus Pfizer’s TKI Inlyta (axitinib), after the combination treatment received FDA approval in the same ... Topline results from the

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Want to give perfect client service? Tough luck, you’re human
In this article an ex-client of mine, Liz Skrbkova, and I explore the (unhelpful) pressures of trying to perfect the client-agency relationship...
WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....

Infographics